Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study

Background Treatment for localized prostate cancer remains controversial. To our knowledge, there are no outcome studies from contemporary population-based cohorts that include data on stage, Gleason score, and serum levels of prostate-specific antigen (PSA). Methods In the National Prostate Cancer Register of Sweden Follow-up Study, a nationwide cohort, we identified 6849 patients aged 70 years or younger. Inclusion criteria were diagnosis with local clinical stage T1–2 prostate cancer from January 1, 1997, through December 31, 2002, a Gleason score of 7 or less, a serum PSA level of less than 20 ng/mL, and treatment with surveillance (including active surveillance and watchful waiting, n = 2021) or curative intent (including radical prostatectomy, n = 3399, and radiation therapy, n = 1429). Among the 6849 patients, 2686 had low-risk prostate cancer (ie, clinical stage T1, Gleason score 2-6, and serum PSA level of <10 ng/mL). The study cohort was linked to the Cause of Death Register, and cumulative incidence of death from prostate cancer and competing causes was calculated. Results For the combination of low- and intermediate-risk prostate cancers, calculated cumulative 10-year prostate cancer–specific mortality was 3.6% (95% confidence interval [CI] = 2.7% to 4.8%) in the surveillance group and 2.7% (95% CI = 2.1% to 3.45) in the curative intent group. For those with low-risk disease, the corresponding values were 2.4% (95% CI = 1.2% to 4.1%) among the 1085 patients in the surveillance group and 0.7% (95% CI = 0.3% to 1.4%) among the 1601 patients in the curative intent group. The 10-year risk of dying from competing causes was 19.2% (95% CI = 17.2% to 21.3%) in the surveillance group and 10.2% (95% CI = 9.0% to 11.4%) in the curative intent group. Conclusion A 10-year prostate cancer–specific mortality of 2.4% among patients with low-risk prostate cancer in the surveillance group indicates that surveillance may be a suitable treatment option for many patients with low-risk disease.

[1]  L. Holmberg,et al.  The completeness of the Swedish Cancer Register – a sample survey for year 1998 , 2009, Acta oncologica.

[2]  P. Stattin,et al.  Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. , 2008, The Journal of urology.

[3]  Zhigang Duan,et al.  Limits of observational data in determining outcomes from cancer therapy , 2008, Cancer.

[4]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[5]  C. Parker.  Active surveillance: towards a new paradigm in the management of early prostate cancer. , 2004, The Lancet. Oncology.

[6]  E. Metter,et al.  Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. , 2007, The Journal of urology.

[7]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[8]  S. Yao,et al.  Population-based study of long-term survival in patients with clinically localised prostate cancer , 1997, The Lancet.

[9]  L. Holmberg,et al.  Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005 , 2007, Scandinavian journal of urology and nephrology.

[10]  T. Wilt,et al.  Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer , 2008, Annals of Internal Medicine.

[11]  Jahar B Choudhury,et al.  Non‐parametric confidence interval estimation for competing risks analysis: application to contraceptive data , 2002, Statistics in medicine.

[12]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[13]  H. Quan,et al.  New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. , 2004, Journal of clinical epidemiology.

[14]  L. Klotz.  Active surveillance for prostate cancer: for whom? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Bill Broyles.  Notes , 1907, The Classical Review.

[16]  B. Norlén,et al.  A systematic overview of radiation therapy effects in prostate cancer , 2004, Acta oncologica.

[17]  B Mattsson,et al.  Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. , 1984, Acta radiologica. Oncology.

[18]  Dirk F Moore,et al.  Outcomes of localized prostate cancer following conservative management. , 2009, JAMA.

[19]  Review of current literature , 1993, International Urogynecology Journal.

[20]  L. Holmberg,et al.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. , 2008, Journal of the National Cancer Institute.

[21]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[22]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[23]  L. Klotz.  Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. , 2005, European urology.

[24]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[25]  Yoshiya Yamada,et al.  Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. , 2006, The Journal of urology.

[26]  R. DiPaola,et al.  Contemporary risk profile of prostate cancer in the United States. , 2009, Journal of the National Cancer Institute.

[27]  John T. Wei,et al.  Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. , 2006, Journal of the National Cancer Institute.

[28]  P. Karlsson,et al.  Socio-economic factors and breast cancer survival – a population-based cohort study (Sweden) , 2005, Cancer Causes & Control.

[29]  Hude Quan,et al.  Cross-National Comparative Performance of Three Versions of the ICD-10 Charlson Index , 2007, Medical care.

[30]  Katja Fall,et al.  Reliability of death certificates in prostate cancer patients , 2008, Scandinavian journal of urology and nephrology.

[31]  M S Pepe,et al.  Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? , 1993, Statistics in medicine.

[32]  Donald E Bailey,et al.  Active surveillance for early‐stage prostate cancer , 2008, Cancer.

[33]  Thomas Wheeler,et al.  An analysis of men with clinically localized prostate cancer who deferred definitive therapy. , 2004, The Journal of urology.